Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 15, 2012. The report details GSK's ongoing tender offer to acquire all outstanding shares of Human Genome Sciences (HGS) and its response to HGS's strategic alternatives review process.
Key Financial Metrics
The filing does not provide GSK's consolidated revenue, profit, cash flow, margins, debt, or liquidity figures. Financial data is limited to the specific terms of the proposed acquisition:
- Offer Price: US$13.00 per share in cash.
- Reference Price: US$7.17 per share (HGS closing price on April 18, 2012).
- Premium: 81 percent over the reference price.
- Expected Synergies: At least US$200 million in cost synergies.
Material Changes and Strategic Actions
GSK confirmed it received a renewed invitation from HGS to participate in a strategic alternatives review process but declined to participate. GSK maintains that its existing offer is unconditional regarding due diligence or financing and can be completed expeditiously. The company emphasized its 20-year relationship with HGS and its unique positioning to deliver value through the combination.
Outlook, Risks, and Contingencies
Management Commentary: GSK believes the offer reflects full and fair value and aligns with its long-term strategy of sustainable growth, business model simplification, and disciplined capital deployment. The offer provides HGS shareholders with immediate liquidity and eliminates execution risks associated with HGS's future growth objectives.
Timeline: The tender offer and withdrawal rights are scheduled to expire at 5:00 pm New York City time on Friday, June 29, 2012.
Risks and Contingencies: The closing of the tender offer is subject to the terms and conditions detailed in the offer document filed on Schedule TO with the SEC. The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties, including those related to the potential business combination.
Key Facts for Investor Verification
- Verify the status of the tender offer expiration on June 29, 2012.
- Review the Schedule TO filings (May 10 and May 23, 2012) for detailed terms and conditions of the offer.
- Confirm whether HGS accepts the offer or proceeds with the strategic alternatives review process beyond the July 16, 2012 proposal deadline.
- Assess the realization of the projected US$200 million in cost synergies post-acquisition.